Physician profile
Brian S Putka
NPI 1346284890
$2,647.74
in general payments reported to CMS, 2019-2025
23 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $176 · 2021: $373 · 2022: $488 · 2023: $211 · 2024: $394 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $855.90 | 2019-2025 | |
| Janssen Biotech, INC. | $197.20 | 2019-2024 | Stelara |
| Celgene Corporation | $177.81 | 2022-2024 | Zeposia |
| Pfizer INC. | $172.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.26 | 2019-2025 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $141.56 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $129.23 | 2023-2025 | Vowst |
| Ethicon US, LLC | $105.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.85 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $89.77 | 2020-2023 | Dificid |
| Braintree Laboratories, INC. | $74.40 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $64.07 | 2021-2023 | |
| Qol Medical, LLC | $58.84 | 2021-2025 | Sucraid |
| Celltrion USA INC. | $57.78 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $55.09 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.42 | 2023-2025 | |
| Madrigal Pharmaceuticals | $46.02 | 2025 | Rezdiffra |
| Ucb, INC. | $24.92 | 2020 | |
| Allergan, INC. | $23.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $21.24 | 2021 | |
| Lilly USA, LLC | $21.10 | 2024 | Omvoh |
| Boston Scientific Corporation | $17.30 | 2025 | Resolution 360 Ultra Clip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Putka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.